Recombinant ORM2 for nonalcoholic fatty liver disease and NASH

Administration of recombinant ORM2, an anti-inflammatory acute phase protein predominantly secreted by hepatocytes, could help treat nonalcoholic fatty liver disease and NASH by decreasing fatty acid uptake.

RNA sequencing of liver tissue in mice fed a high-fat diet identified higher ORM2 expression in mice resistant to obesity and nonalcoholic fatty liver disease than in obese mice with nonalcoholic fatty liver disease, and analysis of public data sets showed hepatic ORM2 expression was higher in obese patients and mice than non-obese individuals. ...